iRadimed Sees Q3 Adj EPS $0.54-$0.59 vs $0.52 Est; Sees Sales $23.000M-$24.500M vs $23.650M Est

Benzinga Newsdesk www.benzinga.com Neutral 75.2%

Neg 0% Neu 75.2% Pos 0%

iRadimed (NASDAQ:IRMD) is looking for Q3 Adj EPS of $0.54-$0.59 vs $0.52 analyst estimate. sees sales of $23.000 million-$24.500 million vs $23.650 million analyst estimate.